Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

sanofi winthrop industrie - rasburíkasa - blóðsykurshækkun - Öll önnur lækningavörur - meðferð og fyrirbyggja bráð hyperuricaemia, til að koma í veg skyndilega nýrnabilun, í fullorðnir, börn og unglingar (aldrinum 0 til 17 ára) með blóðfræðileg illkynja með hár æxli byrði og í hættu á hraðri æxli lysis eða rýrnun á upphaf lyfjameðferð.

Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

sloan pharma s.a.r.l - botulinum eiturefni tegund b - torticollis - vöðvaslakandi lyf - neurobloc er ætlað til meðferðar á leghálsi (torticollis). sjá kafla 5. 1 fyrir gögn um virkni í sjúklingar móttækilegur / þola að botox tegund.

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

abcur ab* - noradrenalinum tartrat (norepinephrinum tartrat) - innrennslisþykkni, lausn - 1 mg/ml

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter holding b.v.* - sodium citrate; sodium chloride - blóðsíunarlausn - 18/140 mmól/l

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - midazolamum hýdróklóríð - stungulyf/innrennslislyf, lausn - 5 mg/ml

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 1 mg/ml

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

prothya biosolutions netherlands b.v. - human albumin - innrennslislyf, lausn - 40 g/l

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - midazolamum hýdróklóríð - stungulyf/innrennslislyf, lausn - 1 mg/ml

Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizúmab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - Ónæmisbælandi lyf - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - einstofna mótefni - Áður ómeðhöndlað langvarandi eitilfrumuhvítblæði (cll): arzerra ásamt klórambúcíl eða bendamustine er ætlað fyrir sjúklinga með cll sem hafa ekki fengið áður en meðferð og hver ert ekki hæf til flúdarabín byggir meðferð. fallið cll: arzerra er ætlað ásamt flúdarabín og cýklófosfamíði fyrir meðferð fullorðinn sjúklinga með fallið cll. svarar cll: arzerra er ætlað fyrir meðferð cll í sjúklingum sem svarar til flúdarabín og alemtuzumab.